Abstract 2359
Background
The role of hormonal therapy in the treatment of advanced ovarian cancer (OC) has not been determined yet. Recently the hormone maintenance therapy (HMT) has been actively discussed.
Methods
70 patients (pts) with serous and endometrioid OC stage Ic-IV after 1st line chemotherapy (CT) with paclitaxel/platinum agents and complete (CR) or partial response (PR) were enrolled in phase II study. Pts received HMT with letrozole 2,5 mg per day for 5 years or until disease progression. 71 pts with the same criteria who observed after 1st line CT was taken as retrospective control group. The groups were comparable at baseline including BRCA1/2 status. Paraffin-embedded material (N = 141) after cytoreductive surgery was assessed for presence of estrogen/progesterone receptors (ER/PR) (IGH) and Ki67 in both groups.
Results
Median progression-free survival (PFS) and overall survival (OS) after letrozole maintenance were 18.7 and 51.2 months respectively. In retrospective analysis PFS was significantly longer in letrozole group than in observational group (18.7 and 16.9 months, p = 0.05; HR 0.68, 95%CI 0.44-0.98). There was no any significant difference in overall survival in HMT and observational groups. In the observational group 26 (36,6%) pts received hormone therapy for disease progression later. The expression of ER, PR and Ki67 didn’t have any prognostic and predictive role. Multivariate Cox regression analysis for PFS showed that administration of HMT, stage and response after CT associated with significantly longer PFS. Based on subgroup analysis only pts with stage III-IV with CR after 1st line had significantly longer PFS than pts who underwent observation: 20.9 vs 17.7 months (p = 0.05; HR 0.56, 95%CI 0.32-0.99).
Conclusions
HMT with letrozole could be effective in pts with advanced serous and endometriod OC stage III-IV with CR after 1st line CT regardless of tumour grade. Further randomized studies of HMT are needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4546 - Efficacy and toxicity of weekly carboplatin and paclitaxel as induction or palliative treatment in advanced esophageal cancer patients
Presenter: Femke de Man
Session: Poster Display session 2
Resources:
Abstract
5908 - Perioperative chemotherapy with Docetaxel, Oxaliplatin, Fluorouracil and Leucovorin (FLOT) versus Epirubicin, Platinum and Capecitabine or Flourouracil (EOX/ECF) in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma- Safety and response data from India.
Presenter: Tanuj Chawla
Session: Poster Display session 2
Resources:
Abstract
937 - Phase II Study of Preoperative Radiotherapy Combined with S-1 plus Cisplatin in Clinically Resectable Type 4 or Large Type 3 Gastric Cancer: OGSG1205
Presenter: Shunji Endo
Session: Poster Display session 2
Resources:
Abstract
1119 - Observational Study of the Peritoneal Washing Cytology Positive Gastric Cancer without Gross Peritoneal Metastasis Underwent Radical D2 Gastrectomy.
Presenter: Jun Eul Hwang
Session: Poster Display session 2
Resources:
Abstract
3744 - Primary results of multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII)
Presenter: Akira Miki
Session: Poster Display session 2
Resources:
Abstract
5091 - Multicenter Phase I/II Feasibility Study of Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction (GMBH-STO-0114)
Presenter: Kathrin Heinrich
Session: Poster Display session 2
Resources:
Abstract
2891 - A phase I study of Docetaxel/Oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction
Presenter: Kei Hosoda
Session: Poster Display session 2
Resources:
Abstract
2994 - Apatinib combined with docetaxel in second-line treatment of advanced gastric cancer: a prospective clinical study (Data updated)
Presenter: Mudan Yang
Session: Poster Display session 2
Resources:
Abstract
3000 - A multicenter phase II study of TAS-114 in combination with S-1 in patients with pre-treated advanced gastric cancer (EPOC1604)
Presenter: Daisuke Takahari
Session: Poster Display session 2
Resources:
Abstract
4653 - Impact of Pembrolizumab (pembro) Versus Paclitaxel on Health-Related Quality of Life (HRQoL) in Patients With Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer That Has Progressed After First-Line Chemotherapy (KEYNOTE-061)
Presenter: Eric Van Cutsem
Session: Poster Display session 2
Resources:
Abstract